Anland Health has completed nearly 100 million yuan in Series A financing.

On August 18, Anlande Pharmaceutical announced the completion of nearly 100 million yuan in Series A financing, exclusively invested by Qiming Venture Partners. The funds raised in this round will primarily be used to accelerate the registration clinical trial process of the core product OpusOne in China, as well as to fully support the application and conduct of its early-stage clinical trials overseas.